Chemotherapy最新文献_第10页

Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer. 延长浆液性卵巢癌术前新辅助化疗周期:寻求最佳周期数。

IF 3.3 4区医学

Chemotherapy Pub Date : 2022-01-01 Epub Date: 2021-11-16 DOI: 10.1159/000519615

Yagmur Minareci, Hamdullah Sozen, Naziye Ak, Ozgur A Tosun, Pınar Saip, M Yavuz Salihoglu, Samet Topuz

{"title":"Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer.","authors":"Yagmur Minareci, Hamdullah Sozen, Naziye Ak, Ozgur A Tosun, Pınar Saip, M Yavuz Salihoglu, Samet Topuz","doi":"10.1159/000519615","DOIUrl":"https://doi.org/10.1159/000519615","url":null,"abstract":"Aim: The optimal number of neoadjuvant chemotherapy (NACT) cycles is unclear in epithelial ovarian cancer. Our study aimed to evaluate the effect of the number of NACT cycles before interval debulking surgery on survival.Methods: Data of 221 patients with advanced-stage serous epithelial ovarian cancer (EOC) were retrospectively evaluated. The patients were divided into groups as who received 3 cycles of NACT (group A), 4-5 cycles of NACT (group B), and 6 cycles of NACT (group C).Results: There were 67 (30%) patients in group A, 70 (32%) in group B, and 84 (38%) in group C. Median overall survival (OS) was 61 (range 43-79) months for group A, 44 (range 36-52) months for group B, and 39 (range 27-50) months for group C. In addition, median disease-free survival (DFS) was 23.1 (range 8.5-32.1) months for group A, 19.2 (range 10.1-28.4) months for group B, and 21.5 (range 16-27) months for group C. Patients receiving >3 NACT cycles had worse OS than patients who received 3 NACT cycles (for group A vs. B, p = 0.018; for group A vs. C, p = 0.049). However, in terms of DFS, patients receiving 3 NACT cycles had no statistically significant difference compared to patients who received >3 NACT cycles.Conclusions: Patients with advanced-stage serous EOC who received more than 3 cycles of NACT had poor OS. However, there was no statistical difference in terms of DFS. In addition, >3 cycles of NACT did not increase the probability of achieving complete cytoreduction at the time of surgery.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":"67 1","pages":"1-11"},"PeriodicalIF":3.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39896041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Contents, Vol. 66, 2021 目录，第66卷，2021年

IF 3.3 4区医学

Chemotherapy Pub Date : 2021-12-01 DOI: 10.1159/000520921

引用次数: 0

Acknowledgement to Reviewers 审稿人致谢

IF 3.3 4区医学

Chemotherapy Pub Date : 2021-12-01 DOI: 10.1159/000520920

引用次数: 0

Front & Back Matter 正面和背面

IF 3.3 4区医学

Chemotherapy Pub Date : 2021-10-01 DOI: 10.1159/000520121

引用次数: 0

Front & Back Matter 正面和背面

IF 3.3 4区医学

Chemotherapy Pub Date : 2021-06-01 DOI: 10.1159/000517678

引用次数: 0

Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab. 人口腔鳞状细胞癌胶原凝胶滴浸培养药敏试验中紫杉醇的最佳接触浓度及与西妥昔单抗联合用药的评估

IF 3.3 4区医学

Chemotherapy Pub Date : 2021-02-09 DOI: 10.1159/000512542

Tomoyuki Kii, Kaname Sakuma, Akira Tanaka

{"title":"Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab.","authors":"Tomoyuki Kii, Kaname Sakuma, Akira Tanaka","doi":"10.1159/000512542","DOIUrl":"10.1159/000512542","url":null,"abstract":"Objective: A combination of the taxane anticancer drug paclitaxel (PTX) and molecular target drug cetuximab (cMab) is effective for the treatment of head and neck squamous cell carcinoma (HNSCC). However, its use is associated with serious side effects, such as neuropathy and myelosuppression. In addition, it is administered regardless of patient sensitivity because biomarkers indicating its efficacy are unavailable. Therefore, we investigated the usefulness of setting the indicated contact concentration of PTX and predicted the antitumor effect of combined contact with cMab using the collagen gel droplet-embedded culture drug sensitivity test (CD-DST).Method: Twelve human oral squamous cell carcinoma (OSCC) cell lines (i.e., SAS, HSC-2, HSC-3, HSC-4, OSC-19, OSC-20, KON, HO-1-N-1, HO-1-u-1, SAT, SCC-4, and Nialym) were used. Using the CD-DST, we calculated the optimal contact concentration of the cells with PTX based on the clinical response rate of HNSCC and evaluated the combined contact with cMab. Furthermore, nude mice were treated with standalone PTX and PTX + cMab, and the results were compared with those of the CD-DST.Results: Based on the CD-DST, 0.1 μg/mL was the optimal contact concentration of PTX, to which the cells showed dose-dependent sensitivity. Moreover, the CD-DST method was used to evaluate the antitumor effects on OSCC even when PTX was used in combination with cMab. The antitumor effects in the CD-DST and nude mice were correlated (p < 0.05).Conclusion: The CD-DST results suggested that it was possible to predict the clinical effects of single-contact PTX and the enhancing effect of cMab + PTX.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":"65 5-6","pages":"147-157"},"PeriodicalIF":3.3,"publicationDate":"2021-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25349779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Managing the Journey of Patients under Chemotherapy in a Pandemic Era: A Nursing Perspective. 大流行病时代化疗患者的旅程管理：护理视角。

IF 3.3 4区医学

Chemotherapy Pub Date : 2021-02-04 DOI: 10.1159/000513140

Raffaella Gualandi, Anna De Benedictis, Maria Grazia De Marinis, Daniela Tartaglini